simon_robertson

Immodulon Therapeutics makes two senior hires

pharmafile | June 17, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Immodulon Therapeutics 

UK late-stage biopharma firm Immodulon Therapeutics has made two new senior appointments to its board of directors. 

Investment fund manager Anthony Bolton, and Sir Simon Robertson (pictured) who is the deputy chairman of HSBC are joining Immodulon as non-executive directors with immediate effect. 

Bolton joined investment services firm Fidelity in 1979 and has managed several funds, including the Fidelity Special Situations which he ran for 28 years up to 2007. Retiring from fund management in 2014 he remains a board member and adviser at Fidelity.

Advertisement

Sir Simon joined the board of HSBC in 2006 and has served on a number of board committees. He has an extensive background in international corporate advisory work, and experience in mergers and acquisitions and financial markets.

Immodulon chairman Charles Akle says: “Anthony and Simon will bring a wealth of commercial experience and insight to the Immodulon Board as we focus on our future development and progress towards Phase III of our lead product, IMM-101, in pancreatic cancer. We look forward to benefitting from their experience and counsel.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content